NTBLQ (Notable Labs) Debt-to-Asset : 0.16 (As of Jun. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Notable Labs Debt-to-Asset?

Notable Labs's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.55 Mil. Notable Labs's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $1.25 Mil. Notable Labs's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was $11.00 Mil. Notable Labs's debt to asset for the quarter that ended in Jun. 2024 was 0.16.

Notable Labs Debt-to-Asset Historical Data

The historical data trend for Notable Labs's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Notable Labs Debt-to-Asset Chart

Notable Labs Annual Data

Trend

Dec21

Dec22

Dec23

Debt-to-Asset

0.22

0.07

0.11

Notable Labs Quarterly Data
	Dec21	Dec22	Mar23	Jun23	Dec23	Mar24	Jun24
Debt-to-Asset	Get a 7-Day Free Trial			-	-	0.11	0.12	0.16

Competitive Comparison of Notable Labs's Debt-to-Asset

For the Biotechnology subindustry, Notable Labs's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Notable Labs's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Notable Labs's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Notable Labs's Debt-to-Asset falls into.

Notable Labs Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Notable Labs's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.523	+	1.526)	/	19.541
	=	0.10

Notable Labs's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.546	+	1.249)	/	11.004
	=	0.16

Notable Labs (OTCPK:NTBLQ) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Notable Labs Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Notable Labs's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Notable Labs Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Notable Labs Ltd (OTCPK:NTBLQ) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

320 Hatch Drive, Foster City, CA, USA, 94404

Website

https://notablelabs.com

Notable Labs Ltd is a clinical-stage platform therapeutics company developing predictive precision medicines for patients with cancer. Through its proprietary Predictive Precision Medicines Platform (PPMP), Notable bio-simulates a cancer treatment to predict whether or not a patient is likely to respond to that specific therapeutic. PPMP is designed to enable Notable to identify and select patients expected to be clinically responsive before the initiation of their treatment and potentially enable fast-track therapeutic development in this patient population.